Tourmaline Bio Inc. | Small-cap | Healthcare
$47.87
-0.06%
| Tourmaline Bio Stock Comparison:
Tourmaline Bio vs VertexTourmaline Bio vs RegeneronTourmaline Bio vs Vera TherapeuticsTourmaline Bio vs Dyne TherapeuticsTourmaline Bio vs LiquidiaTourmaline Bio vs S&P 500 | Market
TL;DR Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

TL;DR: Financial Overview - Revenue, Profits & Key Metrics

Latest Quarterly: Jun 2025

Income Metrics

Revenue 0
Operating Income -26.0M
Net Income -23.1M
EPS (Diluted) $-0.90

Balance Sheet Metrics

Total Assets 287.5M
Total Liabilities 7.6M
Shareholders Equity 279.9M
Debt to Equity 0.03

Cash Flow Metrics

Operating Cash Flow -21.9M
Free Cash Flow -21.7M

Revenue & Profitability Trend

Tourmaline Bio Income Statement From 2022 to 2024

Metric202420232022
Revenue i000
Cost of Goods Sold i---
Gross Profit i---
Gross Margin % i0.0%0.0%0.0%
Operating Expenses
Research & Development i67.0M32.4M17.5M
Selling, General & Administrative i22.7M13.0M2.2M
Other Operating Expenses i---
Total Operating Expenses i89.7M45.4M19.7M
Operating Income i-89.7M-45.4M-19.7M
Operating Margin % i0.0%0.0%0.0%
Non-Operating Items
Interest Income i---
Interest Expense i---
Other Non-Operating Income16.5M3.3M-
Pre-tax Income i-73.2M-42.1M-19.7M
Income Tax i---
Effective Tax Rate % i0.0%0.0%0.0%
Net Income i-73.2M-42.1M-19.7M
Net Margin % i0.0%0.0%0.0%
Key Metrics
EBITDA i-89.7M-45.4M-19.7M
EPS (Basic) i$-2.89$-8.87$-0.97
EPS (Diluted) i$-2.89$-8.87$-0.97
Basic Shares Outstanding i25348000474700020336773
Diluted Shares Outstanding i25348000474700020336773

Income Statement Trend

Tourmaline Bio Balance Sheet From 2020 to 2024

Metric20242023202220212020
Assets
Current Assets
Cash & Equivalents i30.5M140.7M8.3M150.0K17.6M
Short-term Investments i227.8M62.2M0-131.9M
Accounts Receivable i-----
Inventory i-----
Other Current Assets10.5M5.9M54.0K-76.0K
Total Current Assets i268.8M208.9M8.3M150.0K150.8M
Non-Current Assets
Property, Plant & Equipment i212.0K362.0K489.0K02.7M
Goodwill i-----
Intangible Assets i-----
Long-term Investments-----
Other Non-Current Assets3.3M974.0K216.0K-14.0K
Total Non-Current Assets i40.2M1.4M786.0K02.0M
Total Assets i309.0M210.3M9.1M150.0K152.8M
Liabilities
Current Liabilities
Accounts Payable i3.6M1.1M401.0K194.0K767.0K
Short-term Debt i227.0K221.0K162.0K150.0K-
Current Portion of Long-term Debt-----
Other Current Liabilities-----
Total Current Liabilities i8.9M5.0M1.4M376.0K3.4M
Non-Current Liabilities
Long-term Debt i17.0K194.0K342.0K0-
Deferred Tax Liabilities i-----
Other Non-Current Liabilities23.0K57.0K--1.4M
Total Non-Current Liabilities i40.0K251.0K27.5M01.4M
Total Liabilities i8.9M5.3M28.8M376.0K4.8M
Equity
Common Stock i3.0K2.0K003.0K
Retained Earnings i-135.3M-62.1M-19.9M-226.0K-43.0M
Treasury Stock i-----
Other Equity-----
Total Shareholders Equity i300.1M205.0M-19.7M-226.0K148.0M
Key Metrics
Total Debt i244.0K415.0K504.0K150.0K0
Working Capital i259.9M203.9M6.9M-226.0K147.3M

Balance Sheet Composition

Tourmaline Bio Cash Flow Statement From 2022 to 2024

Metric202420232022
Operating Activities
Net Income i-73.2M-42.1M-19.7M
Depreciation & Amortization i39.0K33.0K6.0K
Stock-Based Compensation i6.6M5.8M195.0K
Working Capital Changes i61.0K-878.0K193.0K
Operating Cash Flow i-66.4M-28.3M-7.2M
Investing Activities
Capital Expenditures i-9.0K-56.0K-68.0K
Acquisitions i---
Investment Purchases i-366.1M-16.6M0
Investment Sales i171.8M20.5M0
Investing Cash Flow i-194.3M3.8M-68.0K
Financing Activities
Share Repurchases i---
Dividends Paid i---
Debt Issuance i-0250.0K
Debt Repayment i-0-400.0K
Financing Cash Flow i161.4M156.6M19.7M
Free Cash Flow i-77.3M-28.1M-11.5M
Net Change in Cash i-99.3M132.2M12.5M

Cash Flow Trend

Tourmaline Bio Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) -16.57
Forward P/E -13.16
Price to Book 4.75
PEG Ratio -0.51

Profitability Ratios

Profit Margin 0.00%
Operating Margin 0.00%
Return on Equity -29.62%
Return on Assets -20.85%

Financial Health

Current Ratio 24.68
Debt to Equity 0.06

Per Share Data

EPS (TTM) $-3.44
Book Value per Share $10.09
Revenue per Share $0.00

Peer Financial Comparison

CompanyMarket CapP/E RatioP/B RatioROEProfit MarginDebt/Equity
trml1.2B-16.574.75-29.62%0.00%0.06
Vertex 103.4B28.686.0222.77%31.86%8.89
Regeneron 63.8B15.132.0915.34%31.37%9.04
Vera Therapeutics 2.0B-10.964.11-54.84%0.00%16.56
Dyne Therapeutics 2.0B-3.882.61-61.32%0.00%21.19
Liquidia 1.9B-13.51126.72-389.13%58.00%1,319.26

Financial data is updated regularly. All figures are in the company's reporting currency.